{Reference Type}: Journal Article
{Title}: Susceptibility of <em>Neisseria gonorrhoeae</em> against a dual treatment antibiotics regimen in primary health centres in Surabaya, Indonesia.
{Author}: Hidayati AN;Sawitri ;Rositawati A;Wardhani PH;Bintanjoyo L;
{Journal}: Aust J Gen Pract
{Volume}: 53
{Issue}: 7
{Year}: 2024 Jul
暂无{DOI}: 10.31128/AJGP-05-23-6845
{Abstract}: <B>OBJECTIVE: </B>There were 82.4 million new gonorrhoea cases worldwide in 2020. Dual treatment with ceftriaxone or cefixime and azithromycin or doxycycline is currently recommended for gonorrhoea in Indonesia. However, reduced susceptibility and resistance to cephalosporins and azithromycin are increasing. We evaluated the susceptibility pattern of Neisseria gonorrhoeae to cefixime, ceftriaxone, azithromycin and doxycycline.<BR><B>METHODS: </B>N. gonorrhoeae isolates were obtained from 19 male participants with clinically and laboratory-confirmed gonorrhoea. Antibiotic susceptibility testing was conducted by disc diffusion and interpreted according to Clinical and Laboratory Standards Institute and Centers for Disease Control and Prevention criteria.<BR><B>RESULTS: </B>Reduced susceptibility or resistance was observed against doxycycline in 19 isolates (100%), cefixime in six (31.6%), ceftriaxone in three (15.8%) and azithromycin in zero (0%) isolates.<BR><B>CONCLUSIONS: </B>A dual treatment regimen with ceftriaxone and azithromycin can still be recommended as first-line therapy for gonorrhoea in Indonesia. Antibiotic susceptibility surveillance of N. gonorrhoeae should be routinely conducted.